Suggestions
John Fox
Healthcare Innovator and Physician Leader
John Fox is the Senior Medical Director for the Americas at Illumina, a role he has held since November 2021. In this position, he focuses on market access, translating the clinical value of molecular genomics and precision medicine to health plan decision-makers, employers, and benefits management companies. His goal is to ensure global access to genomic technologies that enhance human health.12
Fox has a strong background in healthcare innovation and clinical transformation. Before joining Illumina, he served as the Vice President of Clinical Transformation at Spectrum Health and held various leadership roles at Priority Health, including Associate Chief Medical Officer and Medical Director. His expertise encompasses oncology care transformation, specialty drug evaluations, and value-based contracts.12
In addition to his corporate roles, Fox is the Chief Boundary Spanner at Foxworthy Healthcare Consulting, where he helps organizations bridge gaps between business and healthcare.1 He is also recognized for his contributions to public health, having served as an Epidemic Intelligence Service Officer at the CDC.1
Highlights
In a story published in November 2023, ProPublica highlighted how health plans find ways to circumvent state healthcare mandates (https://lnkd.in/gd8yb3Xg). The article highlights one family's efforts to obtain healthcare benefits for what would be a fatal hematologic malignancy, and how the health plan thwarted those efforts. The surviving family members have had their story heard and it's had an impact. The Michigan Department of Insurance and Financial Services issue guidance to Michigan health plans saying they can't dodge paying for expensive new cancer treatments (https://lnkd.in/gsBPTGhy less than two months after publication of the study).
In the last year, the American Cancer Society and Cancer Action Network have been effective in passage of state mandates, requiring insurers to pay for testing to determine if patients are eligible for personalized, precision medicines to treat cancer. Whether patients benefit from these mandates will depend a) on how health plans implement them, and b) whether there is regulatory oversight to identify and enforce the mandates by state regulators. I have received many responses to the ProPublica article. A common question has been, “Why now? Why 2023 when these events unfolded in 2017-2019?” Two responses. First, the family needed time to grieve and their experience was central to highlighting the injustice. Second, is there a statute of limitations on justice? The truth of the Tulsa, Oklahoma massacre are still being discovered more than 100 years later. Lastly, I had some trepidation working with investigative reporters, especially being misquoted or misrepresented. To my delight and satisfaction, the ProPublica reporters, Maya Miller and Robin Fields, held themselves to the highest ethical standards and reported only what they could independently verify. They confirmed my belief in their integrity and more importantly, value of investigative journalism to expose abuse of power and betrayals of trust.
I'm excited to attend this year's Patient-Centered Oncology Care event! Come join me by registering here. https://lnkd.in/gcqMcWbT #AJMC #PCOC2022
